Wegener's Granulomatosis (Granulomatosis with Polyangiitis)
Overview
Wegener’s granulomatosis, now more commonly called Granulomatosis with Polyangiitis (GPA), is a rare, autoimmune, necrotizing vasculitis that primarily affects small‑ and medium‑sized blood vessels. The disease causes inflammation and granuloma formation in the respiratory tract (nose, sinuses, lungs) and can involve the kidneys, skin, eyes, ears, and nervous system.
- Prevalence: Approximately 3–10 cases per million people worldwide (CDC, Mayo Clinic).
- Typical age of onset: 40‑60 years, though children and younger adults can be affected.
- Gender: Slight male predominance (about 1.2 : 1).
- Geography: Occurs worldwide; higher incidence reported in Northern Europe and North America.
Symptoms
Because GPA can involve many organ systems, symptoms are often a combination of respiratory, renal, and systemic signs. The presentation may be acute, sub‑acute, or chronic.
Upper Respiratory Tract
- Chronic sinusitis – persistent nasal congestion, facial pain, or pressure.
- Nasal ulceration or crusting – often painless, may cause nosebleeds (epistaxis).
- Sore throat / hoarseness – due to granulomas in the larynx.
- Otitis media – recurrent ear infections or hearing loss.
Lower Respiratory Tract
- Cough – dry or productive.
- Hemoptysis – coughing up blood (can be massive).
- Shortness of breath – especially on exertion.
- Chest pain – pleuritic or due to lung nodules.
Kidneys (Renal Involvement)
- Hematuria – blood in the urine, often microscopic.
- Proteinuria – foamy urine, an early sign of glomerulonephritis.
- Decreased urine output – indicating worsening renal function.
Systemic / General
- Fever, chills, night sweats – low‑grade or high‑grade.
- Fatigue, weight loss – common but nonspecific.
- Arthralgias – joint pain without swelling.
- Skin lesions – palpable purpura, livedo reticularis, or ulcers.
- Eye involvement – scleritis, conjunctivitis, or vision changes.
- Neurologic findings – mononeuritis multiplex, facial palsy.
Causes and Risk Factors
The exact trigger for GPA remains unknown, but several mechanisms and risk factors have been identified.
- Autoimmune dysregulation: The hallmark is the presence of anti‑neutrophil cytoplasmic antibodies (ANCA), especially proteinase‑3 ANCA (PR3‑ANCA). These antibodies activate neutrophils, leading to vessel wall damage.
- Genetic predisposition: Certain HLA‑DQ alleles (e.g., HLA‑DQβ1*04) and genes involved in immune regulation increase susceptibility (NIH).
- Environmental exposures: Silica dust, metal fumes, and certain infections (e.g., Staphylococcus aureus colonization) have been associated with higher risk.
- Smoking: Current or former smokers have a modestly increased risk.
- Age & gender: Middle‑aged adults, especially males, are most frequently diagnosed.
Diagnosis
Diagnosing GPA requires a combination of clinical suspicion, laboratory testing, imaging, and often tissue biopsy.
Laboratory Tests
- ANCA testing:
- PR3‑ANCA (c‑ANCA) – positive in ~70‑80% of generalized GPA.
- MPO‑ANCA (p‑ANCA) – less common, seen in limited disease.
- Complete blood count (CBC) – may show anemia or leukocytosis.
- Renal panel – serum creatinine, BUN, electrolytes to assess kidney function.
- Urinalysis – hematuria, red blood cell casts indicative of glomerulonephritis.
- Inflammatory markers – ESR and CRP are often elevated.
Imaging
- Chest X‑ray / CT scan: Detects nodules, cavitary lesions, or infiltrates.
- Sinus CT: Shows mucosal thickening, bony erosion, or sinus opacification.
- Renal ultrasound: Evaluates kidney size and obstruction; not diagnostic but useful.
Biopsy
The gold standard is a tissue biopsy showing necrotizing granulomatous inflammation and vasculitis. Common sites:
- Nasopharyngeal tissue (nasal ulcer or sinus biopsy)
- Skin lesions
- Kidney (renal biopsy) – especially when renal involvement is prominent
- Lung (transbronchial or video‑assisted thoracoscopic biopsy)
Classification Criteria
The 2022 ACR/EULAR classification criteria for GPA assign points for clinical features, ANCA status, and histology. A score ≥5 classifies a patient as having GPA (NEJM).
Treatment Options
Rapid control of inflammation is essential to prevent organ damage. Treatment is divided into an induction phase (rapid disease control) and a maintenance phase (prevent relapse).
Induction Therapy
- High‑dose glucocorticoids: Prednisone 1 mg/kg/day (max 60 mg) tapered over 4–6 months.
- Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2–3 weeks). Historically the standard.
- Rituximab: Anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks or 1 g on days 1 and 15. Preferred for patients desiring fertility preservation or with severe renal disease (Cleveland Clinic).
- Plasma exchange (PLEX): Considered in severe pulmonary hemorrhage or rapidly progressive glomerulonephritis (evidence mixed; used per physician judgment).
Maintenance Therapy
- Rituximab: 500 mg every 6 months for 2–4 years.
- Azazathioprine: 2 mg/kg/day.
- Methotrexate: 15–25 mg weekly (if renal function is adequate).
- Mycophenolate mofetil: 1–1.5 g twice daily – an alternative for patients intolerant to azathioprine.
- Low‑dose glucocorticoids (≤10 mg/day) are usually continued for the first year of maintenance.
Adjunctive Measures
- Prophylaxis against opportunistic infections (e.g., trimethoprim‑sulfamethoxazole for Staphylococcus aureus colonization and Pneumocystis jirovecii pneumonia).
- Vaccinations: influenza, pneumococcal, hepatitis B, COVID‑19 (administer before immunosuppression when possible).
- Bone health: calcium, vitamin D, and bisphosphonates if on long‑term steroids.
- Fertility counseling: discuss sperm banking or oocyte preservation before cyclophosphamide.
Living with Wegener's Granulomatosis
Managing a chronic autoimmune condition involves medical, emotional, and practical strategies.
Daily Management Tips
- Medication adherence: Use pill organizers, set alarms, and keep a medication list for each provider.
- Monitor labs regularly: CBC, liver/kidney function, and ANCA titers per your rheumatologist’s schedule.
- Track symptoms: Keep a diary of sinus issues, cough, urine changes, and fatigue to spot early relapses.
- Hydration & kidney health: Drink adequate fluids (unless limited by renal disease) and avoid NSAIDs, which can worsen kidney function.
- Skin care: Moisturize to prevent fissures, protect ulcerated areas, and promptly treat infections.
- Respiratory hygiene: Use saline nasal rinses, humidifiers, and avoid smoke or strong chemicals.
- Physical activity: Low‑impact exercise (walking, swimming, yoga) improves stamina without overtaxing the joints or lungs.
- Stress management: Mindfulness, counseling, or support groups can reduce disease‑flaring stress.
- Regular follow‑up: See your rheumatologist every 3–6 months during remission and more often if new symptoms arise.
Support Resources
- Vasculitis Foundation (vasculitisfoundation.org)
- American College of Rheumatology patient education portal
- Local or online GPA support groups
Prevention
Because GPA is an autoimmune disease with unknown primary cause, primary prevention is limited. However, patients and clinicians can reduce triggers that may precipitate flares:
- Avoid cigarette smoke and occupational silica exposure.
- Prompt treatment of chronic sinus infections to limit bacterial colonization.
- Vaccinations to prevent infections that could trigger immune activation.
- Maintain good oral hygiene – dental infections have been linked to vasculitis flares.
Complications
If left untreated or poorly controlled, GPA can lead to serious, often irreversible damage.
- Renal failure: Crescentic glomerulonephritis can progress to end‑stage kidney disease requiring dialysis or transplant.
- Upper airway obstruction: Nasal septal perforation, saddle‑nose deformity, or subglottic stenosis.
- Pulmonary hemorrhage: Life‑threatening bleeding into the lungs.
- Peripheral neuropathy: Mononeuritis multiplex causing weakness or sensory loss.
- Cardiovascular disease: Accelerated atherosclerosis from chronic inflammation and steroid use.
- Ocular complications: Scleritis, uveitis, or vision loss.
- Increased infection risk: Due to immunosuppressive therapy.
When to Seek Emergency Care
- Sudden, severe shortness of breath or coughing up large amounts of blood.
- Rapidly worsening kidney function (e.g., decreased urine output, swelling of legs/face, sudden rise in blood pressure).
- High fever (> 102 °F/38.9 °C) with chills, confusion, or severe headache.
- Acute vision changes, eye pain, or sudden loss of sight.
- Severe, persistent abdominal pain or gastrointestinal bleeding.
**References**
- Mayo Clinic. Granulomatosis with Polyangiitis (Wegener’s). https://www.mayoclinic.org
- Cleveland Clinic. Granulomatosis with Polyangiitis (GPA). https://my.clevelandclinic.org
- CDC. Vasculitis Fact Sheet. https://www.cdc.gov
- National Institutes of Health (NIH). ANCA-associated Vasculitis. https://www.ncbi.nlm.nih.gov
- New England Journal of Medicine. 2022 ACR/EULAR Classification Criteria for GPA. https://www.nejm.org
- World Health Organization. WHO Guidelines for Immunization. https://www.who.int